Skip to Main Content

Paper Details

FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
J Am Soc Nephrol
119
2018
AMP, AMP-activated protein kinase, Bile acids, C57BL/6J, Diabetes, FXR, G protein-coupled receptor TGR5, INT-767, INT-777, NADH, Nephropathy, Nrf-1, OCA, Obesity, PGC, PGC-1, TGR5, cholesterol, diabetes, diabetes- and obesity-related kidney disease, diabetic, diabetic nephropathy, estrogen, estrogen-related receptor-, fatty acid, kidney fibrosis, mice, nephropathy, nuclear hormone receptor farnesoid X receptor, obesity, obeticholic acid, podocyte, proteinuria, sirtuin 1, sirtuin 3, streptozotocin, tubulointerstitial fibrosis, type 2 diabetes
Author NameAffiliation
Avi Z RosenbergNational Institute of Diabetes and Digestive and Kidney Diseases and.
Avi Z Rosenberg
Avi Z RosenbergNational Institute of Diabetes and Digestive and Kidney Diseases and.
Avi Z Rosenberg
Jeffrey B KoppNational Institute of Diabetes and Digestive and Kidney Diseases and.
Dana A HillCenter for Genetic Medicine Research, Children's Research Institute, Children's National Medical Center and the George Washington University School of Medicine and Health Sciences
Dana A HillRabin Medical Center
Marshall Scott Lucia
Marshall Scott LuciaUniversity of Colorado Denver and Department of Veterans Affairs Medical Center
David J Orlicky
David J OrlickyUniversity of Colorado Denver and Department of Veterans Affairs Medical Center
Vivette D D'AgatiColumbia University College of Physicians and Surgeons
Vivette D D'AgatiColumbia University College of Physicians and Surgeons
Frank J GonzalezNational Cancer Institute, National Institutes of Health
  • 1 - 14

Datasets

Release 1.2